Pb1747: outcome of childhood alltreated with all bfm ic 2009 protocol

Topic: 2. Acute lymphoblastic leukemia - Clinical Background: Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy, accounting for 25% of all childhood cancers. Management of childhood ALL has greatly improved over the past decades. Our institution has been using ALL BFM IC 2009 protocol since January, 2016 and before this time we were using Modified St Jude protocols. Aims: Our aim is to identifys clinical and laboratory findings, risk groups, and outcomes of childhood ALL treated with ALL BFM IC 2009 protocol in a single tertiary center in Turkey. Methods: In this retrospective study, patients who have been diagnosed with ALL between 01 January 2016 and 31 December 2022 were included. There were 92 patients who were eligible for the study, 43 of those were female (46,7%) and 49 were male (53,3%). Median age at diagnosis was 77 months (13-212)and 49 patients (53,3%) being older than 5 years at the time of diagnose Results: There were, 85 patients (92,4%) were diagnosed with pre-B cell and seven patients (7,6%) with T cell ALL. Six patients (6,5%) and 2 patients (2,2%) were positive for t(9,22) and t(4,11), respectively. At day 8, 10 patients (10,9%) were diagnosed as poor prednisone responder. Risk stratification assesment was done on day 1, 8, 15 and 33 according to the ALL BFM IC 2009 protocol. Twenty-five patient (27,2%) were recorded as standart risk (SR), 50 patients (54,3%) as intermediate risk (IR), 17 patients (18,5%) as high risk (HR). Central nervous system involvement at diagnosis was identified in 10 (11%) patients. Relapse was observed in eight patients (8,7%); 5 of them (62,5%) being isolated bone marrow, 2 (25%) isolated testicle and 1 (12,5%) being combined relapses (bone marrow and testicle). Seven of the relapse cases (87,5%) occured within the first 60 months of the treatment. Four patients (4,3%) died during their treatment or follow up and all were either relapse or refractory cases. Five year overall survival and event free survival rates were 93±3,and 85,4±5,2 %, respectively. When compared survival rates according to initial findings(age1-5 years and ≥6 years),gender,WBC count(<20x109/l vs ≥ 20x109/l);CNS involvement (CNS(+) vs CNS(-),day15 MRD level(<0,1% vs ≥0,1%) and risk groups were not statistically different between each groups(p>0.05). Summary/Conclusion: Acute lymphoblastic leukemia is the most common malignancy in childhood. Risk assessment, risk based therapy and adequate treatment of complications play major roles in survival. Although, 32 (36,36%) out of 88 were still on treatment, 5 year EFS and OS rates was found to be comparable with the major treatment protocols. Keywords: ALL